HomeCompareLBPS vs PLD

LBPS vs PLD: Dividend Comparison 2026

LBPS yields 121.21% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LBPS wins by $2.44M in total portfolio value
10 years
LBPS
LBPS
● Live price
121.21%
Share price
$1.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.95M
Annual income
$3,410,602.48
Full LBPS calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — LBPS vs PLD

📍 LBPS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLBPSPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LBPS + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LBPS pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LBPS
Annual income on $10K today (after 15% tax)
$10,303.03/yr
After 10yr DRIP, annual income (after tax)
$2,899,012.11/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PLD beats the other by $1,568,958.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LBPS + PLD for your $10,000?

LBPS: 50%PLD: 50%
100% PLD50/50100% LBPS
Portfolio after 10yr
$7.72M
Annual income
$4,333,519.33/yr
Blended yield
56.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

LBPS
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LBPS buys
0
PLD buys
0
No recent congressional trades found for LBPS or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLBPSPLD
Forward yield121.21%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$8.95M$6.50M
Annual income after 10y$3,410,602.48$5,256,436.18
Total dividends collected$8.14M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: LBPS vs PLD ($10,000, DRIP)

YearLBPS PortfolioLBPS Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$22,821$12,121.21$11,255$555.24+$11.6KLBPS
2$50,271$25,852.41$13,062$1,018.59+$37.2KLBPS
3$107,013$53,222.70$15,903$1,926.67+$91.1KLBPS
4$220,388$105,884.01$20,839$3,823.32+$199.5KLBPS
5$439,612$203,797.23$30,464$8,166.08+$409.1KLBPS
6$850,309$379,924.02$52,054$19,457.30+$798.3KLBPS
7$1,596,614$686,783.92$109,886$54,188.93+$1.49MLBPS
8$2,913,579$1,205,201.50$304,030$186,451.18+$2.61MLBPS
9$5,172,959$2,055,429.68$1,166,125$840,813.32+$4.01MLBPS
10$8,945,669$3,410,602.48$6,504,190$5,256,436.18+$2.44MLBPS

LBPS vs PLD: Complete Analysis 2026

LBPSStock

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Full LBPS Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this LBPS vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LBPS vs SCHDLBPS vs JEPILBPS vs OLBPS vs KOLBPS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.